IonQ enters its June 16 earnings with a peculiar set of contradictions: short sellers are still covering a 55% monthly rally, options hedgers remain more defensive than usual, and the Street is stretched between a $35 neutral and a $100 bull target — all with a quarter due in less than two weeks.
The short cover story has not materially changed since the notes published May 28 and May 30, but the data has ticked further in the same direction. Short interest now stands at 20.3% of the free float, down from the 23–24% range that held through mid-May. That represents roughly 13 million shares returned to lenders over the past month. The most dramatic episode in this unwind came in the week of May 19–22, when availability briefly collapsed to near zero — fewer than one share available for every 500 already borrowed. It has since recovered to 8.8%, which remains tight but is no longer extreme. Cost to borrow has stayed remarkably subdued throughout, running at 1.27%. Borrow costs this low, alongside an easing availability, point to orderly position reduction rather than a distressed short squeeze. The ORTEX short score of 69.3 reflects a still-elevated but gradually declining bearish positioning.
Options traders are not fully buying the relief. The put/call ratio has edged to 1.11, more than 1.7 standard deviations above its 20-day average of 1.05. That is below the near-two standard deviation reading flagged in the May 30 note, but still firmly in defensive territory. It is also well below the 52-week high of 1.42, so the hedging has not reached panic levels. The setup looks like selective protection ahead of a known event — earnings on June 16 — rather than a broad bearish repositioning.
The analyst picture is mixed, and the gap between bulls and bears is unusually wide. The most recent activity came on May 7, when JP Morgan raised its target to $50 from $42 while holding Neutral, and Wedbush lifted its target to $75 from $60 while reiterating Outperform. With IonQ now trading at $71.40, the JP Morgan neutral target implies the stock is already stretched, while the Wedbush Outperform is now barely above current price. The consensus sits at Hold with a mean target of $67.63 — actually below the current price, a sign that much of the recent 55% monthly gain has moved the stock ahead of Street models. Rosenblatt maintains a $100 Buy as the top-end outlier. The bull case centres on quantum computing-as-a-service momentum and a beat-and-raise Q1 print. Bears point to the pending SkyWater Technology acquisition, which remains subject to regulatory approval and is adding execution risk to an already loss-making business. The price-to-book has expanded to 5.8x over the past month, a re-rating driven entirely by price rather than book value growth.
Institutional flows offer one genuinely positive signal in the noise. Morgan Stanley Investment Management added 958,700 shares in the April reporting period. Goldman Sachs added 1.68 million shares in Q1. Defiance ETFs added nearly 9 million shares — though much of that likely reflects ETF rebalancing tied to quantum thematic products rather than active conviction. On the insider side, the picture is less encouraging. The Executive Chairman, CEO, CFO and Company Secretary all sold in March at prices between $33 and $35, well below today's $71. These were modest in scale and appear to be routine plan sales, but the direction of travel from insiders has been consistently outward.
The last earnings print on May 6 produced only a -0.7% one-day move. The five-day reaction was a different matter: IonQ gained 15% in the week following results, which aligns with the broader cover rally that subsequently ran through May. June 16 is now the next focal point. Whether the remaining 20% short interest proves to be stubborn conviction or further fuel for covering is the question the data alone cannot answer.
See the live data behind this article on ORTEX.
Open IONQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
